HepatitisCvirus(HCV)infectionremainsoneofthemaincausesofchronicliverdiseaseworldwide.Theadventofdirect-actingantivirals(DAAs)hassignificantlyimprovedthecourseofpatientswithchronicHCVinfection(CHC),duetotheabilityofthesedrugstoachievehighratesofsustainedvirologicalresponse(SVR).TheseexceedinglyhighratesofSVRandtheexcellentsafetydatahavebeenconfirmedinreallifepractice.Evolvingguidelineshavebeenissuedbynationalandinternationalscientificsoci-etiesinaccordancewiththeprogressionofclinicalknowledgeandtheavailabilityofnewDAAs.Theserecommendations,however,maynotbeapplieduniversallybecauseofdelaysindrugsreimbursabilityindifferentcountriesandbecausesomeNationalHealthSystemsidentifyonlypatientswithadvanceddiseaseasatreatmentpriority.ItalyinthisregardisaprototypeaboutDAAstreatmentofCHCpatients.WiththeaimtoassesstheItaliantreatmentexperiencewithDAAsandtorespondtounmetneedsintreatmentoptimizationofantiviraltherapyinspecificsettingsofCHCpatients,agroupofItalianexpertsmetinStresainFebruary2017.Thesummaryoftheconsiderationsarisingfromthistwo-daymeetingandsomestatementsregardingafewopenissuesarereportedinthispositionpaper.©2017EditriceGastroenterologicaItalianaS.r.l.PublishedbyElsevierLtd.Allrightsreserved.
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel / Viganã², Mauro; Perno, Carlo Federico; Craxã¬, Antonio; Aghemo, Alessio; Alberti, Alfredo; Andreone, Pietro; Andreoni, Massimo; Bonora, Stefano; Brunetto, Maurizia Rossana; Bruno, Raffaele; Bruno, Savino; Calvaruso, Vincenza; Caporaso, Nicola; Ceccherini-Silberstein, Francesca; Cento, Valeria; Ciancio, Alessia; Colombatto, Piero; Degasperi, Elisabetta; Di Marco, Vito; Di Perri, Giovanni; D'Offizi, Gianpiero; Fagiuoli, Stefano; Ferrari, Carlo; Gaeta, Giovanni Battista; Pellicelli, Adriano; Petta, Salvatore; Piovesan, Sara; Puoti, Massimo; Raimondo, Giovanni; Russo, Francesco Paolo; Taliani, Gloria; Trama, Ugo; Villa, Erica; Zignego, Anna Linda. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 49:7(2017), pp. 731-741. [10.1016/j.dld.2017.03.027]
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel
Caporaso, Nicola;Taliani, Gloria;
2017
Abstract
HepatitisCvirus(HCV)infectionremainsoneofthemaincausesofchronicliverdiseaseworldwide.Theadventofdirect-actingantivirals(DAAs)hassignificantlyimprovedthecourseofpatientswithchronicHCVinfection(CHC),duetotheabilityofthesedrugstoachievehighratesofsustainedvirologicalresponse(SVR).TheseexceedinglyhighratesofSVRandtheexcellentsafetydatahavebeenconfirmedinreallifepractice.Evolvingguidelineshavebeenissuedbynationalandinternationalscientificsoci-etiesinaccordancewiththeprogressionofclinicalknowledgeandtheavailabilityofnewDAAs.Theserecommendations,however,maynotbeapplieduniversallybecauseofdelaysindrugsreimbursabilityindifferentcountriesandbecausesomeNationalHealthSystemsidentifyonlypatientswithadvanceddiseaseasatreatmentpriority.ItalyinthisregardisaprototypeaboutDAAstreatmentofCHCpatients.WiththeaimtoassesstheItaliantreatmentexperiencewithDAAsandtorespondtounmetneedsintreatmentoptimizationofantiviraltherapyinspecificsettingsofCHCpatients,agroupofItalianexpertsmetinStresainFebruary2017.Thesummaryoftheconsiderationsarisingfromthistwo-daymeetingandsomestatementsregardingafewopenissuesarereportedinthispositionpaper.©2017EditriceGastroenterologicaItalianaS.r.l.PublishedbyElsevierLtd.Allrightsreserved.File | Dimensione | Formato | |
---|---|---|---|
Viganò_treatment-hepatitis_2017.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
813.58 kB
Formato
Adobe PDF
|
813.58 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.